NVAX:NASDAQ
Novavax Inc
$10.80
arrow_upward
+1.60%(+0.17) 1D
$10.87
arrow_upward
+0.65% (+0.070)todayPre-market
Closed: Sep 28, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$10.50
High
$10.98
Low
$10.26
Mkt. cap
1.78B
Avg. vol.
5.68M
Volume
6.81K
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
Open
$10.50
High
$10.98
Low
$10.26
Mkt. cap
1.78B
Avg. vol.
5.68M
Volume
6.81K
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Zacks
·
13 hours ago
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Yahoo Finance UK
·
14 hours ago
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Yahoo Finance UK
·
23 hours ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com